NEXT GENERATION CANCER DIAGNOSTIC MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-159781 | Health Care
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Next Generation Cancer Diagnostic Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET
7.1 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTIC MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 GE Healthcare (United States)
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Koninklijke Philips N.V. (Netherlands)
16.3 F. Hoffmann-La Roche Ltd (Switzerland)
16.4 Qiagen (Germany)
16.5 Novartis AG (Switzerland)
16.6 Abbott (United States)
16.7 Thermo Fisher Scientific, Inc. (United States)
16.8 Opko Health, Inc. (United States)
16.9 Myriad Genetics, Inc (United States)
16.10 Agilent Technologies (United States)
16.11 Cepheid
16.12 PerkinElmer
16.13 Genomic Health, Inc.
16.14 Illumina, Inc.
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By ApplicationBiomarker Development
CTC Analysis
Proteomic Analysis
Epigenetic Analysis
Genetic Analysis
By Function
Therapeutic Monitoring
Companion Diagnostics
Prognostics
Cancer Screening
Risk Analysis
By Technology
Next Generation Sequencing
QPCR & Multiplexing
Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
Protein Microarrays
DNA Microarrays
By End User
Academic Institutes & Research Centres
Hospitals & Clinics
Pharmaceutical & Biotechnology Companies
Other End Users
By Cancer
Lung Cancer
Breast Cancer
Colorectal Cancer
Cervical Cancer
Others
Companies
GE Healthcare (United States)
Koninklijke Philips N.V. (Netherlands)
F. Hoffmann-La Roche Ltd (Switzerland)
Qiagen (Germany)
Novartis AG (Switzerland)
Abbott (United States)
Thermo Fisher Scientific, Inc. (United States)
Opko Health, Inc. (United States)
Myriad Genetics, Inc (United States)
Agilent Technologies (United States)
Cepheid
PerkinElmer
Genomic Health, Inc.
Illumina, Inc.
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.